Does Blue Cross Blue Shield of Arizona Cover Eliquis?

How BCBSAZ Lists Eliquis on Its Formulary

Blue Cross Blue Shield of Arizona places Eliquis (apixaban) on the preferred brand tier across the majority of its plan types. This means the drug is covered, but members pay more than they would for a generic medication. The exact copay depends on the plan purchased, whether the member has met their deductible, and whether they use a preferred pharmacy.

Commercial Plan Tiers

On most BCBSAZ commercial PPO and HMO plans, Eliquis appears on Tier 3 (preferred brand). Members with a standard three-tier benefit design can expect copays between $50 and $90 per 30-day supply before applying any manufacturer assistance. Some high-deductible health plans (HDHPs) require the member to pay the full negotiated price until the deductible is met, which can exceed $500 per month for a brand-name anticoagulant 1.

Medicare Advantage Formulary Placement

BCBSAZ Medicare Advantage plans also list Eliquis, though the tier and cost-sharing structure differ from commercial products. Under Part D coverage, Eliquis often falls on Tier 3 or Tier 4 depending on the specific Medicare Advantage plan design. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully in effect since 2025, provides significant financial protection for Medicare enrollees taking Eliquis year-round 2.

Marketplace (ACA) Plans

Arizona marketplace plans offered through BCBSAZ follow a separate formulary. Eliquis coverage on these plans varies by metal tier (Bronze, Silver, Gold, Platinum). Gold and Platinum plans typically offer fixed copays for preferred brands, while Bronze and Silver plans may require full cost-sharing until the deductible is met.

What Eliquis Costs with BCBSAZ Insurance

Out-of-pocket expense depends on the intersection of formulary tier, deductible status, and any available copay assistance. Without insurance, Eliquis carries a wholesale acquisition cost of approximately $580 to $620 for a 30-day supply of the standard 5 mg twice-daily dose 3.

Copay Card and Assistance Programs

Bristol-Myers Squibb offers a copay savings card that reduces out-of-pocket costs to as little as $10 per month for commercially insured patients. This card cannot be used with Medicare, Medicaid, or other federal healthcare programs. Eligible patients can save up to $6,400 per year through this program.

For Medicare enrollees, the Extra Help (Low-Income Subsidy) program through the Social Security Administration can reduce Part D copays to $0 to $11 per prescription, depending on income and asset thresholds.

Cost Comparison: Eliquis vs. Warfarin

Warfarin, the older vitamin K antagonist, costs $4 to $15 per month as a generic. However, warfarin requires regular INR monitoring (typically every 2 to 4 weeks), dietary restrictions, and carries a higher risk of intracranial hemorrhage. The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% compared to warfarin (HR 0.79, 95% CI 0.66 to 0.95) while also reducing major bleeding by 31% (HR 0.69, 95% CI 0.60 to 0.80) in patients with atrial fibrillation 4. The total cost of care, including lab monitoring and bleeding-related hospitalizations, may favor apixaban despite its higher drug price.

Prior Authorization and Step Therapy Rules

BCBSAZ does not uniformly require prior authorization for Eliquis across all plan types, but certain situations trigger additional review.

When Prior Authorization Applies

Prior authorization is most commonly required on Medicare Advantage plans and on some employer-sponsored group plans with restrictive formulary management. The insurer typically asks prescribers to document one of the following FDA-approved indications:

• Reduction of stroke and systemic embolism risk in nonvalvular atrial fibrillation
• Treatment of deep vein thrombosis (DVT)
• Treatment of pulmonary embolism (PE)
• Prophylaxis of DVT following hip or knee replacement surgery
• Reduction in risk of recurrent DVT and PE after initial therapy

The American College of Cardiology (ACC) and American Heart Association (AHA) 2019 guidelines on atrial fibrillation management recommend direct oral anticoagulants (DOACs) including apixaban over warfarin for most patients with nonvalvular AF (Class I recommendation) 5. Citing this guideline in prior authorization paperwork strengthens approval chances.

Step Therapy Considerations

BCBSAZ does not typically impose step therapy (requiring trial and failure of a cheaper drug first) for Eliquis when prescribed for an FDA-approved indication. However, some self-funded employer plans administered by BCBSAZ may include step therapy requiring documentation that warfarin is inappropriate, contraindicated, or previously failed.

Turnaround Time for Prior Authorization

Standard prior authorization requests are processed within 72 hours. Urgent requests tied to hospital discharge or acute VTE treatment receive expedited review within 24 hours. If denied, members have 180 days to file an internal appeal.

Clinical Evidence Supporting Eliquis Coverage

Insurance formulary committees base coverage decisions on efficacy, safety, and cost-effectiveness data. Eliquis has one of the strongest evidence profiles among the DOACs.

The ARISTOTLE Trial

The landmark ARISTOTLE trial randomized 18,201 patients with atrial fibrillation and at least one stroke risk factor to apixaban 5 mg twice daily or dose-adjusted warfarin 4. Apixaban reduced the primary endpoint of stroke or systemic embolism (1.27% vs. 1.60% per year, P=0.01 for superiority). All-cause mortality was lower with apixaban (3.52% vs. 3.94% per year, P=0.047). Dr. Christopher Granger, the trial's lead investigator, stated: "Apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality."

The AMPLIFY Trial

For venous thromboembolism treatment, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional enoxaparin/warfarin therapy for recurrent VTE (2.3% vs. 2.7%, P<0.001 for noninferiority) while reducing major bleeding by 69% (0.6% vs. 1.8%, relative risk 0.31) 6. This bleeding advantage is why many formulary committees maintain Eliquis in a preferred position.

Real-World Safety Data

A 2022 retrospective cohort study published in the Journal of the American College of Cardiology analyzing over 100,000 new DOAC users found that apixaban was associated with the lowest rates of gastrointestinal bleeding among the four available DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) 7. The American College of Chest Physicians (CHEST) 2021 guidelines cite apixaban as a first-line option for VTE treatment, noting: "We suggest apixaban or rivaroxaban over vitamin K antagonist therapy for initial treatment of DVT or PE in patients without cancer" 8.

What to Do If BCBSAZ Denies Eliquis Coverage

A denial does not mean the decision is final. Multiple pathways exist to obtain coverage.

Filing a Formulary Exception

Members or their prescribers can request a formulary exception by submitting clinical documentation explaining why Eliquis is medically necessary. Common reasons include:

• History of labile INR on warfarin
• Inability to comply with warfarin's dietary restrictions or monitoring schedule
• Prior intracranial hemorrhage or high HAS-BLED score favoring a DOAC with lower bleeding risk
• Drug interactions that make warfarin management unsafe (e.g., concurrent amiodarone, fluconazole)

Internal and External Appeals

If the formulary exception is denied, BCBSAZ members can file an internal appeal within 180 days. If the internal appeal is also denied, Arizona law permits an external review by an independent review organization (IRO). The Arizona Department of Insurance, Financial Institutions and Securities oversees this process.

Switching to a Covered Alternative

If coverage remains unavailable, other DOACs that may be on a preferred tier include rivaroxaban (Xarelto) or, on some plans, generic options. Rivaroxaban has once-daily dosing for AF but showed higher rates of gastrointestinal bleeding compared to apixaban in head-to-head observational analyses 7.

Generic Apixaban and Future Cost Changes

The patent field for Eliquis has been shifting. Bristol-Myers Squibb and Pfizer reached settlements with multiple generic manufacturers allowing market entry of generic apixaban beginning in 2026 9. As generics become available, BCBSAZ will likely move generic apixaban to a lower formulary tier (Tier 1 or Tier 2), substantially reducing member cost-sharing.

What Generic Entry Means for Members

Once generic apixaban achieves broad pharmacy availability, monthly out-of-pocket costs could fall to $10 to $30 for most commercially insured members. Medicare Part D enrollees would also see reduced costs, potentially placing the generic in the $0 to $15 copay range on many plans.

Should You Switch to Generic When Available?

The FDA requires generic drugs to demonstrate bioequivalence to the brand-name product, meaning the same active ingredient at the same dose produces the same blood levels 10. Switching from brand Eliquis to generic apixaban is considered clinically appropriate by the FDA and most professional societies.

How to Verify Your Specific BCBSAZ Coverage

Formulary details vary by plan. Take these steps to confirm your coverage.

Check the Online Formulary Tool

BCBSAZ publishes searchable formulary documents for each plan year on its member portal. Log in, manage to "Pharmacy Benefits," and search for "apixaban" or "Eliquis" to see your plan's specific tier, prior authorization requirements, and quantity limits.

Call Member Services

The number on the back of your BCBSAZ insurance card connects you to a representative who can confirm Eliquis coverage, provide a cost estimate based on your deductible status, and explain any prior authorization steps.

Ask Your Pharmacist for a Test Claim

Your pharmacist can run a test claim (also called a "dry run" or eligibility check) through the BCBSAZ pharmacy benefit manager to determine the exact copay before you commit to filling the prescription. This takes about five minutes and provides the most accurate cost estimate.

Eliquis Dosing and Monitoring Basics

Understanding the standard dosing helps ensure your prescription aligns with what your insurance expects to approve.

Standard Doses

For atrial fibrillation: 5 mg twice daily is the standard dose. A reduced dose of 2.5 mg twice daily applies if the patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher 3.

For DVT/PE treatment: 10 mg twice daily for 7 days, followed by 5 mg twice daily for at least 6 months.

For DVT/PE prophylaxis after initial treatment: 2.5 mg twice daily.

Monitoring Requirements

Unlike warfarin, apixaban does not require routine blood monitoring. No INR checks are needed. Prescribers typically assess renal function (serum creatinine and estimated GFR) at baseline and annually, since apixaban is partially eliminated by the kidneys (approximately 27%) 11. Hepatic function should also be assessed at baseline, as apixaban is metabolized by CYP3A4.

Patients taking apixaban should inform their prescriber before starting any new medication, particularly strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) or inducers (rifampin, carbamazepine, phenytoin), as these can significantly alter apixaban blood levels 3.